Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)

SUPPLEMENTARY MATERIAL 1

List of studies excluded at full-text screening stage, with brief reasons

Reason of exclusion	Source
Other study design (e.g. reviews)	1–25,26–35,36–50,51–70,62,71–89,90–114,115–144,145–169,170–192
Non-economic evaluations	193–207,208–237,138,139,238–247
Conference abstract that has journal article published	157,341–39459,248–266,267–291,292–300
Non-screening (i.e. not related to antenatal or newborn screening)	301–323
No details of economic evaluation presented in Methods/Results	324–333
Duplicate	334–340
Health preference studies	341–343

References

1 Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J, *et al.* A review and critique of modelling in prioritising and designing screening programmes. *Health Technology Assessment* 2007;**11**:iii–137.

2 Cacciatore P, Visser LA, Buyukkaramikli N, van der Ploeg CPB, van den Akker-van Marle ME. The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review. *International Journal of Neonatal Screening* 2020;**6**:. https://doi.org/10.3390/ijns6040094.

3 Langer A, Holle R, John J. Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening. *BMC Health Services Research* 2012;**12**:300.

4 Anonymous. Cost-effectiveness of voluntary prenatal and routine newborn HIV screening. *AIDS Reader* 2001;**11**:81.

5 Anonymous. Non-invasive Prenatal Testing: A Review of the Cost Effectiveness and Guidelines. *Canadian Agency for Drugs and Technologies in Health CADTH Rapid Response Reports* 2014;**02**:10.

6 Asciutto R, di Napoli A, Vecchi S, Sicuro J, Mirisola C, Petrelli A. A systematic review of economic evaluations of neonatal and maternal healthcare in immigrant and ethnic minority women. *Epidemiologia e Prevenzione* 2020;**44**:142–52. https://doi.org/10.19191/EP20.5-6.S1.P142.084.

7 Bert F, Gualano MR, Biancone P, Brescia V, Camussi E, Martorana M, *et al.* HIV screening in pregnant women: A systematic review of cost-effectiveness studies. *International Journal of Health Planning and Management* 2018;**33**:31–50.

8 Bobic B, Villena I, Stillwaggon E. Prevention and mitigation of congenital toxoplasmosis. Economic costs and benefits in diverse settings. *Food and Waterborne Parasitology* 2019;**16**:e00058.

9 Bradshaw EA, Martin GR. Screening for critical congenital heart disease: advancing detection in the newborn. *Current Opinion in Pediatrics* 2012;**24**:603–8.

10 Brice P, Jarrett J, Mugford M. Genetic screening for cystic fibrosis: An overview of the science and the economics. *Journal of Cystic Fibrosis* 2007;**6**:255–61.

11 Bryan S, Dormandy E, Roberts T, Ades A, Barton P, Juarez-Garcia A, *et al.* Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. *British Journal of General Practice* 2011;**61**:e620-7.

12 Castilla-Rodriguez I, Vallejo-Torres L, Couce ML, Valcarcel-Nazco C, Mar J, Serrano-Aguilar P. Cost-Effectiveness Methods and Newborn Screening Assessment. *Advances in Experimental Medicine and Biology* 2017;**1031**:267–81.

13 Caughey AB, Kaimal AJ, Odibo AO. Cost-effectiveness of Down syndrome screening paradigms. *Clinics in Laboratory Medicine* 2010;**30**:629–42.

14 Colbourn TE, Asseburg C, Bojke L, Philips Z, Welton NJ, Claxton K, *et al.* Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses. *BMJ* 2007;**335**:655.

15 Colgan S, Gold L, Wirth K, Ching T, Poulakis Z, Rickards F, *et al.* The cost-effectiveness of universal newborn screening for bilateral permanent congenital hearing impairment: systematic review. *Acad Pediatr* 2012;**12**:171–80.

16 Coward S, Leggett L, Kaplan GG, Clement F. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations. *BMJ Open* 2016;**6**:e011821.

17 DeVore GR. Is genetic ultrasound cost-effective? *Seminars in Perinatology* 2003;**27**:173–82.

18 Ewer AK, Furmston AT, Middleton LJ, Deeks JJ, Daniels JP, Pattison HM, *et al.* Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness. *Health Technology Assessment* 2012;**16**:v–xiii, 1.

19 Ferrier C, Dhombres F, Guilbaud L, Durand-Zaleski I, Jouannic JM. Ultrasound screening for birth defects: A medico-economic review. *Gynecologie, Obstetrique, Fertilite and Senologie* 2017;**45**:408–15.

20 Fitria N, van Asselt ADI, Postma MJ. Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review. *European Journal of Health Economics* 2019;**20**:407–17.

21 Garcia-Perez L, Linertova R, Alvarez-de-la-Rosa M, Bayon JC, Imaz-Iglesia I, Ferrer-Rodriguez J, *et al.* Cost-effectiveness of cell-free DNA in maternal blood testing for prenatal detection of trisomy 21, 18 and 13: a systematic review. *European Journal of Health Economics* 2018;**19**:979–91.

22 Geue C, Wu O, Xin Y, Heggie R, Hutchinson S, Martin NK, *et al.* Cost-effectiveness of HBV and HCV screening strategies - A systematic review of existing modelling techniques. *PLoS ONE* 2015;**10**:.

23 Gilbert RE, Peckham CS. Congenital toxoplasmosis in the United Kingdom: To screen or not to screen? *Journal of Medical Screening* 2002;**9**:135–41.

24 Gliddon HD, Peeling RW, Kamb ML, Toskin I, Wi TE, Taylor MM. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. *Sexually Transmitted Infections* 2017;**93**:S3–15.

25 Gonzalez FM, Veneziano MA, Puggina A, Boccia S. A Systematic Review on the Cost-Effectiveness of Genetic and Electrocardiogram Testing for Long QT Syndrome in Infants and Young Adults. *Value in Health* 2015;**18**:700–8.

26 Grosse SD. Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis. *Healthcare* 2015;**3**:1133–57.

27 Grosse SD, Mason CA, Gaffney M, Thomson V, White KR. What Contribution Did Economic Evidence Make to the Adoption of Universal Newborn Hearing Screening Policies in the United States? *International Journal of Neonatal Screening* 2018;**4**:25.

28 Grosse SD, Olney RS, Baily MA. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. *Applied Health Economics & Health Policy* 2005;**4**:239–47.

29 Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. *Public Health Genomics* 2010;**13**:106–15.

30 Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. *Annual Review of Public Health* 2007;**28**:365–91.

31 Grosse SD, Thompson JD, Ding Y, Glass M. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience. *Milbank Quarterly* 2016;**94**:366–91. https://doi.org/10.1016/j.jpeds.2016.01.029.

32 Grosse SD, van Vliet G. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? *Hormone Research* 2007;**67**:284–91.

33 Grosse SD, van Vliet G. Challenges in Assessing the Cost-Effectiveness of Newborn Screening: The Example of Congenital Adrenal Hyperplasia. *International Journal of Neonatal Screening* 2020;**6**:. https://doi.org/10.3390/ijns6040082.

34 Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. *BMC Infectious Diseases* 2013;**13**:181.

35 Hieronimus S, le Meaux JP. Relevance of gestational diabetes mellitus screening and comparison of selective with universal strategies. *Diabetes and Metabolism* 2010;**36**:575–86.

36 Honest H, Forbes C, Durée K, Norman G, Duffy S, Tsourapas A, *et al.* Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. *Health Technology Assessment* 2009;**13**:1–627.

37 Hubbard HB. A primer on economic evaluations related to expansion of newborn screening for genetic and metabolic disorders. *JOGNN: Journal of Obstetric, Gynecologic, & Neonatal Nursing* 2006;**35**:692–9.

38 Huntington S, Weston G, Adams E. *Repeat screening for syphilis in pregnancy as an alternative screening strategy in the UK - a cost-effectiveness analysis*. 2020. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1306%0A (Accessed February 20, 2021).

39 Ibekwe E, Haigh C, Duncan F, Fatoye F. Economic impact of routine opt-out antenatal human immune deficiency virus screening: A systematic review. *Journal of Clinical Nursing* 2017;**26**:3832–42.

40 Institute of Health E. First and Second Trimester Prenatal Screening for Trisomies 13, 18, and 21 and Open Neural Tube Defects. *Institute of Health Economics* 2012;**06**:9.

41 John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. *European Journal of Health Economics* 2019;**20**:1123–31.

42 Kaambwa B, Bryan S, Gray J, Milner P, Daniels J, Khan KS, *et al.* Cost-effectiveness of rapid tests and other existing strategies for screening and management of early-onset group B streptococcus during labour. *BJOG: An International Journal of Obstetrics & Gynaecology* 2010;**117**:1616–27.

43 Kobrynski L. Newborn screening for severe combined immune deficiency (technical and political aspects). *Current Opinion in Allergy and Clinical Immunology* 2015;**15**:539–46.

44 Krauth C. Health economic analysis of screening. *Gms Current Topics in Otorhinolaryngology Head and Neck Surgery* 2008;**7**:Doc01. https://doi.org/10.1542/peds.110.5.855.

45 Kubiak C, Jyonouchi S, Kuo C, Garcia-Lloret M, Dorsey MJ, Sleasman J, *et al.* Fiscal implications of newborn screening in the diagnosis of severe combined immunodeficiency. *Journal of Allergy and Clinical Immunology in Practice* 2014;**2**:697–702.

46 Langer A, John J. Newborn screening and health economics - A challenging relationship. *Monatsschrift Fur Kinderheilkunde* 2009;**157**:1230–6.

47 Lees CM, Davies S, Dezateux C. Neonatal screening for sickle cell disease. *Cochrane Database of Systematic Reviews* 2000:CD001913.

48 Lipstein EA, Vorono S, Browning MF, Green NS, Kemper AR, Knapp AA, *et al.* Systematic evidence review of newborn screening and treatment of severe combined immunodeficiency. *Pediatrics* 2010;**125**:e1226-35.

49 Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. *International Journal of Gynaecology and Obstetrics* 2011;**115 Suppl**:S20-5.

50 Nargesi S, Rezapour A, Souresrafil A, Dolatshahi Z, Khodaparast F. Cost-Effectiveness Analysis of Pulse Oximetry Screening in the Full-Term Neonates for Diagnosis of Congenital Heart Disease: A Systematic Review. *Iranian Journal of Pediatrics* 2020;**30**:. https://doi.org/10.5812/ijp.105393.

51 Rochau U, Rushaj VQ, Schaffner M, Schonhensch M, Stojkov I, Jahn B, *et al.* Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview. *Thyroid* 2020;**30**:746–58. https://doi.org/10.1089/thy.2018.0776.

52 Rose M, Myers J, Evans J, Prince A, Espinosa C. Hepatitis C virus risk-based vs. universal screening among pregnant women: Implementation and cost-effectiveness analysis. *Hepatology* 2018;**68 (Supple**:55A.

53 Saab S, Kullar R, Khalil H, Gounder P. Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review. *Journal of Clinical Gastroenterology* 2020. https://doi.org/10.1097/MCG.0000000000001360.

54 Santoro SL, Chicoine B, Jasien JM, Kim JL, Stephens M, Bulova P, *et al.* Pneumonia and respiratory infections in Down syndrome: A scoping review of the literature. *American Journal of Medical Genetics Part A* 2021;**185**:286–99. https://doi.org/10.1002/ajmg.a.61924.

55 Schmidt M, Werbrouck A, Verhaeghe N, de Wachter E, Simoens S, Annemans L, *et al.* Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations. *Journal of Cystic Fibrosis* 2018;**17**:306–15.

56 Scott DA, Loveman E, McIntyre L, Waugh N. Screening for gestational diabetes: a systematic review and economic evaluation. *Health Technology Assessment* 2002;**6**:1–161.

57 Sinkey RG, Odibo AO. Cost-Effectiveness of Old and New Technologies for Aneuploidy Screening. *Clinics in Laboratory Medicine* 2016;**36**:237–48.

58 Sparks TN, Caughey AB. How should costs and cost-effectiveness be considered in prenatal genetic testing? *Seminars in Perinatology* 2018;**42**:275–82. https://doi.org/10.1053/j.semperi.2018.07.003.

59 Therrell Jr. BL, Buechner C. Newborn screening for all identifiable disorders with tandem mass spectrometry is cost effective: supporting arguments. *Annals of the Academy of Medicine Singapore* 2008;**37**:32–4.

60 Tita AT, Grobman WA, Rouse DJ. Antenatal herpes serologic screening: an appraisal of the evidence. *Obstetrics and Gynecology* 2006;**108**:1247–53.

61 vande Velde S, Schillemans A, van Biervliet S, Robberecht E. Neonatal screening for cystic fibrosis. *Tijdschrift Voor Geneeskunde* 2004;**60**:1217–24.

62 Waugh N, Royle P, Clar C, Henderson R, Cummins E, Hadden D, *et al.* Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee. *Health Technology Assessment* 2010;**14**:1–83.

63 Weile LK, Kahn JG, Marseille E, Jensen DM, Damm P, Lohse N. Global cost-effectiveness of GDM screening and management: current knowledge and future needs. *Best Practice and Research in Clinical Obstetrics and Gynaecology* 2015;**29**:206–24.

64 Wright SJ, Jones C, Payne K, Dharni N, Ulph F. The Role of Information Provision in Economic Evaluations of Newborn Bloodspot Screening: A Systematic Review. *Applied Health Economics & Health Policy* 2015;**13**:615–26.

65 Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Walker I, *et al.* Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. *British Journal of Haematology* 2005;**131**:80–90.

66 Zakiyah N, Postma MJ, Baker PN, van Asselt AD, Consortium IMpro. Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments. *Pharmacoeconomics* 2015;**33**:1069–82.

67 UK National Screening Committee. *Antenatal screening for Fragile X Syndrome*. 2010. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1168 (Accessed February 17, 2021).

68 UK National Screening Committee. *Repeat screening for syphilis in pregnancy: A cost-effectiveness model*. 2020. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1307 (Accessed February 17, 2021).

69 Chapple J. *Antenatal screening for Toxoplasmosis*. 2015. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1141 (Accessed February 17, 2021).

70 Knowles R, Hunter R. *Screening for Congenital Heart Defects*. 2014. URL: https://legacyscreening.phe.org.uk/documents/pulse-oximetry/CHD and PO First Review Doc.pdf (Accessed February 17, 2021).

71 Cartwright S. *An evaluation of carrier screening for spinal muscular atrophy against the National Screening Committee criteria*. 2012. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=279 (Accessed February 17, 2021).

72 UK National Screening Committee. *Evaluation of Antenatal Screening for Thrombophilia against National Screening Committee Handbook Criteria, with consideration of neonatal*

screening and general population screening. n.d. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1174 (Accessed February 17, 2021).

73 Wood P. *Vasa praevia and placenta praevia screening in pregnancy*. 2013. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1109 (Accessed February 17, 2021).

74 UK National Screening Committee. *Screening for Group B Streptococcal infection in pregnancy*. 2012. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1262 (Accessed February 17, 2021).

75 UK National Screening Committee. *Screening for Group B Streptococcal infection in pregnancy*. 2012. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=499 (Accessed February 17, 2021).

76 Solutions for Public Health. *Screening for antenatal and postnatal mental health problems*. 2019. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1112 (Accessed February 17, 2021).

77 Solutions for Public Health. *Antenatal screening for hepatitis C virus*. 2018. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1064 (Accessed February 17, 2021).

78 UK National Screening Committee. *Newborn screening for cytomegalovirus*. 2017. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1015 (Accessed February 17, 2021).

79 UK National Screening Committee. *Screening for Very Long Chain Acyl Coenzyme A Dehydrogenase Deficiency*. 2014. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1034 (Accessed February 17, 2021).

80 UK National Screening Committee. *Screening for Carnitine Transporter Deficiency*. 2014. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=472 (Accessed February 17, 2021).

81 UK National Screening Committee. *Screening for Tyrosinaemia I*. 2014. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=474 (Accessed February 17, 2021).

82 UK National Screening Committee. *Screening for Citrullinaemia and Argininosuccinate lyase deficiency*. 2014. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1160 (Accessed February 17, 2021).

83 Public Health England. *Recommendation to the UK National Screening Committee (UK NSC) for population screening for critical congenital heart disease and significant non-cardiac conditions using pulse oximetry screening in addition to current routine screening*. n.d. URL: https://legacyscreening.phe.org.uk/documents/pulse-oximetry/PO Research Review.pdf (Accessed February 17, 2021).

84 UK National Screening Committee. *Newborn screening for propionic acidaemia*. 2015. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1102 (Accessed February 17, 2021).

85 UK National Screening Committee. *Screening for Amino Acid Metabolism Disorders Disease*. 2015. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1161 (Accessed February 17, 2021).

86 Chilcott J, Bessey A, Pandor A, Paisley S. *Expanded newborn screening for inborn errors of the metabolism*. 2013. URL:

https://legacyscreening.phe.org.uk/policydb_download.php?doc=416 (Accessed February 17, 2021).

87 UK National Screening Committee. *Screening for Severe Combined Immunodeficiency*. 2012. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1124 (Accessed February 17, 2021).

88 Hill C. *An evaluation of screening for postnatal depression against NSC criteria*. 2010. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=140 (Accessed February 17, 2021).

89 Australian Government Department of Health. *Clinical Practice Guidelines: Pregnancy care (Economic analyses)*. 2018. URL: https://www.health.gov.au/sites/default/files/clinical-practice-guidelines-pregnancy-care-economic-analyses.pdf (Accessed February 17, 2021).

90 Ampersand Health Science. *Evidence evaluation report - Thyroid dysfunction*. 2017. URL: https://consultations.health.gov.au/health-services-division/antenatal-care-guidelines-review/supporting_documents/Thyroid dysfunction evidence evaluation 16May17.docx (Accessed February 17, 2021).

91 Medical Services Advisory Committee. *Genetic test for fragile X syndrome*. 2002. URL: http://www.health.gov.au/internet/msac/publishing.nsf/Content/EA0095D0692554F6CA25801000123B7D/$File/1035-Genetic-test-for-fragile-X-syndrome-Assessment-Report.pdf (Accessed February 17, 2021).

92 Medical Services Advisory Committee. *Application No. 1492 – Non-Invasive Prenatal Testing*. 2018. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/B1BCB2807D09C12DCA258258000F2025/$File/1492 - Final PSD.pdf (Accessed February 17, 2021).

93 Medical Services Advisory Committee. *Application No. 1467 – Obstetric MRI*. 2018. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/3809AECE10C4998CCA2580D5000F0B7C/$File/1467-Final_PSD.pdf (Accessed February 17, 2021).

94 Medical Services Advisory Committee. *Application No. 1573 – Reproductive carrier testing for cystic fibrosis, spinal muscular atrophy and fragile X syndrome*. 2020. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/4EF0E3C5A7CC9D05CA2584240009557E/$File/1573 - Final PSD_Jul2020.docx (Accessed February 17, 2021).

95 Medical Services Advisory Committee. *Application No. 1533 – Genome-wide microarray testing for pregnancies with major fetal structural abnormalities detected by ultrasound*. 2019. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/316E609CD3EC1E8DCA2583350000C6DA/$File/1533 Final PSD.pdf (Accessed February 17, 2021).

96 Medical Services Advisory Committee. *Application 1335 – Point of Care Tests to exclude preterm labour: Phosphorylated Insulin-like Growth Factor Binding Protein test*. 2014. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/4D7B4B53015CDBA1CA25801000123BDD/$File/1335-Final-PSD-accessible.docx (Accessed February 17, 2021).

97 Ampersand Health Science Writing. *Evidence evaluation report - Pre-eclampsia*. 2017. URL: https://consultations.health.gov.au/health-services-division/antenatal-care-guidelines-review/supporting_documents/Preeclampsia evaluation report 16May17.pdf (Accessed February 17, 2021).

98 Medical Services Advisory Committee. *Application No. 1216.1 – Cystic Fibrosis Transmembrane Regulator (CFTR) testing*. 2017. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/4C5CB83B16D72E3FCA25815D001BFB37/$File/1216.1-FinalPSD-accessible.docx (Accessed February 17, 2021).

99 Medical Services Advisory Committee. *Application No. 1216 – Cystic fibrosis transmembrane regulator (CFTR) testing*. 2015. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/D54C11627FEA9785CA25801000123BDC/$File/1216-FinalPSD-CFTR-accessible.docx (Accessed February 17, 2021).

100 Parrella A, Hiller J, Mundy L. *Screening and treatment of Gestational Diabetes Mellitus*. 2005. URL: https://www.health.gov.au/internet/horizon/publishing.nsf/Content/87861CF6758FF75ACA2575AD0080F348/$File/Gestational Diabetes December2005.pdf (Accessed February 17, 2021).

101 Mundy L, Merlin T. *Ultrasound screening for hip dysplasia: A new screening programme for the early detection of hip dysplasia in neonates*. 2003. URL: https://www1.health.gov.au/internet/horizon/publishing.nsf/Content/0F73968BFE0DC379CA2575AD0080F2E6/$File/v2_2.rtf (Accessed February 17, 2021).

102 Australian Government Department of Health. *Group B streptococcus*. n.d. URL: https://consultations.health.gov.au/phd-tobacco/antenatal-care_module-ii/user_uploads/7.5group-b-streptococcus.docx (Accessed February 17, 2021).

103 Australian Government Department of Health. *Newborn Bloodspot Screening Condition Assessment Summary: Congenital Adrenal Hyperplasia (CAH)*. n.d. URL: https://www.health.gov.au/sites/default/files/documents/2020/02/newborn-bloodspot-screening-condition-assessment-summary-congenital-adrenal-hyperplasia_0.pdf (Accessed February 17, 2021).

104 Australian Government Department of Health. *Haemoglobin disorders*. n.d. URL: https://consultations.health.gov.au/phd-tobacco/antenatal-care_module-ii/user_uploads/7.2haemoglobin-disorders.docx (Accessed February 17, 2021).

105 Medical Services Advisory Committee. *Genetic test for fragile X syndrome*. 2002. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/EA0095D0692554F6CA25801000123B7D/$File/1035-Genetic-test-for-fragile-X-syndrome-One-page-Summary.pdf%0A (Accessed February 17, 2021).

106 Gerkens S, Martin N, Thiry N, Hulstaert F. *Hepatitis C: Screening en Preventie*. 2011. URL: https://kce.fgov.be/sites/default/files/atoms/files/KCE_173A_hepatitis_C_2.pdf (Accessed February 17, 2021).

107 Government of Canada. *Why is it important to address Fetal Alcohol Spectrum Disorder (FASD)?*. 2007. URL: https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/hp-ps/dca-dea/prog-ini/fasd-etcaf/publications/pdf/factsheet2-fasd-etcaf-eng.pdf (Accessed February 17, 2021).

108 Canadian Task Force on Preventive Health Care. *Prevention of Early-onset Group B Streptococcal (GBS) Infection in the Newborn: Systematic Review and Recommendations*. 2001. URL: https://canadiantaskforce.ca/wp-content/uploads/2016/09/2002-streptococcal-systematic-review-and-recommendations-en.pdf (Accessed February 17, 2021).

109 Medical Advisory Secretariat. *Neonatal Screening of Inborn Errors of Metabolism Using Tandem Mass Spectrometry: An Evidence-Based Analysis*. 2003. URL: https://www.hqontario.ca/Portals/0/Documents/evidence/reports/rev_tandms_090102.pdf (Accessed February 17, 2021).

110 Turcotte C, Blancquaert I, St-Louis M. *Évaluation de la pertinence du dépistage néonatal sanguin de la galactosémie classique (GALT)*. 2020. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_DepistageNeonatal_GALT.pdf (Accessed February 17, 2021).

111 Brunet J, Blancquaert I, Lalancette-Hébert M, St-Louis M. *Évaluation de la pertinence du dépistage néonatal sanguin du déficit en biotinidase (BIOT)*. 2020. URL:

https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_DepistageNeonatal_Biotinidase.pdf (Accessed February 17, 2021).

112 Brunet J, St-Louis M, Blancquaert I. *Évaluation de la pertinence du dépistage néonatal sanguin par spectrométrie de masse en tandem du déficit en bêta-cétothiolase (βKT)*. 2020. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_DepistageNeonatal_BKT.pdf (Accessed February 17, 2021).

113 Institut national d'excellence en santé et en services sociaux (INESS). *Assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for carnitine uptake deficiency (CUD)*. 2020. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_Neonatal_CUD_Summary.pdf (Accessed February 17, 2021).

114 Létourneau I, Blancquaert I, Lalancette-Hébert M, Brunet J. *Évaluation de la pertinence du dépistage néonatal sanguin par spectrométrie de masse en tandem de l'acidémie isovalérique (IVA)*. 2020. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_DepistageNeonatal_IVA.pdf%0A (Accessed February 17, 2021).

115 Létourneau I, Blancquaert I, Brabant J, Lalancette-Hébert M. *Évaluation de la pertinence du dépistage néonatal sanguin par spectrométrie de masse en tandem du défaut de captation de la carnitine cellulaire (CUD)*. 2020. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_DepistageNeonatal_CUD.pdf%0A (Accessed February 17, 2021).

116 Makni H, St-Hilaire C, Robb L, K L, I B. *Spectrométrie de masse en tandem et dépistage néonatal des erreurs innées du métabolisme*. 2007. URL: https://www.inesss.qc.ca/fileadmin/doc/AETMIS/Rapports/DepistageGenetique/2007_03_Mono.pdf%0A (Accessed February 17, 2021).

117 Côté B, Gosselin C. *Pertinence d'élargir le programme de dépistage néonatal sanguin au Québec*. 2013. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Genetique/INESSS_Depistage_neonatal_sanguin.pdf%0A (Accessed February 17, 2021).

118 Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS). *La spectrométrie de masse en tandem et le dépistage néonatal sanguin au Québec*. 2007. URL: https://www.inesss.qc.ca/fileadmin/doc/AETMIS/Rapports/DepistageGenetique/ETMIS2007_Vol.3_No3.pdf%0A (Accessed February 17, 2021).

119 Brunet J, Blancquaert I, St-Louis M. *Évaluation de la pertinence du dépistage néonatal sanguin par spectrométrie de masse en tandem du déficit en holocarboxylase synthétase (HCS)*. 2020. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_DepistageNeonatal_HCS.pdf%0A (Accessed February 17, 2021).

120 Institut national d'excellence en santé et en services sociaux (INESSS). *Détection des aneuploïdies des chromosomes 13, 18, 21, X et y par QF-PCR*. 2013. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Analyse_biomedicale/Avril_2014/Detection_aneuploidies_chromosomes_13-18-21-X_Y_par_QF-PCR.pdf%0A (Accessed February 17, 2021).

121 Hvas A, Ehlers L, Møller H. *Screening af gravide indvandrere for hæmoglobinopati – en medicinsk teknologivurdering*. 2009. URL: https://www.sst.dk/-/media/Udgivelser/2009/Publ2009/MTV/haemoglobinopati/Screening_gravide_indvandrere_net_final,-d-,pdf.ashx%0A (Accessed February 17, 2021).

122 Gemeinsamer Bundesausschuss. *Kinder-Richtlinie: Screening von Neugeborenen zur Früherkennung von SCID*. 2019. URL: https://www.g-ba.de/downloads/40-268-5426/2018-11-22_Kinder-RL_SCID-Screening_ZD.pdf (Accessed February 17, 2021).

123 Gemeinsamer Bundesausschuss. *Neugeborenen-Hörscreening*. 2008. URL: https://www.g-ba.de/downloads/40-268-759/2008-12-17-Abschluss-Hörscreening.pdf (Accessed February 17, 2021).

124 Lawrenson R. *NSAC "Statement of Advice": Should women be screened for vitamin D during pregnancy in New Zealand?* 2010. URL: https://www.nsu.govt.nz/system/files/page/vitamin-d-screening-during-pregnancy.pdf (Accessed February 17, 2021).

125 Sherwood J. *Chlamydia Screening in New Zealand: Report for the National Screening Unit*. 2006. URL: https://www.nsu.govt.nz/system/files/resources/chlamydia-screening-report.pdf (Accessed February 17, 2021).

126 Williams L, Jackson G. *Screening for SCID - Literature Review*. 2013. URL: https://www.nsu.govt.nz/system/files/resources/screening-severe-combined-immune-deficiency-literature-review.pdf (Accessed February 17, 2021).

127 Lawrenson R. *Gestational Diabetes Mellitus: Should GPs keep a register of everyone with GDM?*. 2010. URL: https://www.nsu.govt.nz/system/files/page/gestational-diabetes-gp-conf-2010-r-lawrenson.pdf (Accessed February 17, 2021).

128 Gjertsen MK, Johansen M, Movik E, Norderhaug IN. *Forebygging av infeksjon med gruppe B-streptokokker i nyfødtperioden*. 2006. URL: https://www.fhi.no/globalassets/dokumenterfiler/notater/2006/notat_06_gbs.pdf (Accessed February 17, 2021).

129 Dorenberg DH, Greve-Isdahl M, Nøkleby H. *Kunnskapsoppsummering: Hepatitt B-undersøkelser i svangerskapet*. 2017. URL: https://www.fhi.no/globalassets/dokumenterfiler/tema/hepatitt/kunnskapsoppsummering-om-hepatitt-b-undersokelser-i-svangerskapet.pdf (Accessed February 17, 2021).

130 Lin JS, Eder M, Bean S. *Screening for Syphilis Infection in Pregnant Women: A Reaffirmation Evidence Update for the U.S. Preventive Services Task Force*. 2018. URL: https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/16875/syphilis-screening-pregnancy-final-evidence-review/pdf (Accessed February 17, 2021).

131 Glass N, Nelson HD, Huffman L. *Screening for Genital Herpes Simplex: Brief Update for the U.S. Preventive Services Task Force*. 2005. URL: https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/733/herpesup/pdf (Accessed February 17, 2021).

132 US Preventive Services Task Force. *Screening for Genital Herpes*. 2005. URL: https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/735/herpesrs/pdf (Accessed February 17, 2021).

133 US Preventive Services Task Force. *Screening for Syphilis Infection*. 2004. URL: https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/qVACAf9sMmuX48MnnVDcBR (Accessed February 17, 2021).

134 Moyer V. Screening for HIV: US preventive services task force recommendation statement. *Annals of Internal Medicine* 2013;**159**:51–60.

135 Donovan L, Hartling L, Muise M, Guthrie A, Vandermeer B, Dryden D. Screening tests for gestational diabetes: a systematic review for the US Preventive Services Task Force. *Annals of Internal Medicine* 2013;**159**:115–22.

136 Berg A, Allan J, Calonge N, Frame P. Screening for HIV: Recommendation Statement. *Annals of Internal Medicine* 2005;**143**:32.

137 Lin K, Barton M. *Screening for Hemoglobinopathies in Newborns: Reaffirmation Update for the U.S. Preventive Services Task Force*. 2007. URL: https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/1051/sicklecelles/pdf (Accessed February 17, 2021).

138 Glass N, Nelson H, Villemyer K. *Screening for Gonorrhea: Update of the Evidence*. 2005. URL: https://uspreventiveservicestaskforce.org/home/getfilebytoken/Wezro6zTSfAWxCrneF-nxB (Accessed February 17, 2021).

139 Glass N, Nelson H, Villemyer K. *Screening for Gonorrhea: Update of the Evidence*. 2005. URL: http://www.uspreventiveservicestaskforce.org/Home/GetFile/1/609/gonup/pdf (Accessed February 17, 2021).

140 Shipman SA, Helfand M, Moyer VA, Yawn BP. *Screening for Developmental Dysplasia of the Hip: A Systematic Literature Review for the U.S. Preventive Services Task Force*. n.d. URL: https://www.uspreventiveservicestaskforce.org/home/getfilebytoken/V3HhneZFw__Vk7L8gwryw3 (Accessed February 17, 2021).

141 Chou R, Cottrell E, Wasson N, Rahman B, Guise J-M. *Screening for Hepatitis C Virus Infection in Adults*. 2012. URL: https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/668/cerhepcscr/pdf (Accessed February 17, 2021).

142 Nelson H, Glass N, Huffman L, Villemyer K, Hamilton A, Frame P, *et al. Screening for Syphilis: Brief Update for the U.S. Preventive Services Task Force*. 2004. URL: https://www.uspreventiveservicestaskforce.org/Home/GetFile/1/991/syphilup/pdf (Accessed February 17, 2021).

143 Hayes I. *Ultrasonography (Ultrasound) in Pregnancy*. 2010. URL: https://www.hca.wa.gov/assets/program/final_report_ultrasound.pdf (Accessed February 17, 2021).

144 Cheng E. *Cell-free DNA prenatal screening for chromosomal aneuploidies*. 2020. URL: https://www.hca.wa.gov/assets/program/htcc-materials-cfdna-20200117.pdf (Accessed February 17, 2021).

145 Center for Evidence-based Policy Oregon Health & Science University. *Cell-free DNA Prenatal Screening for Chromosomal Aneuploidies - Draft key questions: public comment and response*. 2019. URL: https://www.hca.wa.gov/assets/program/cell-free-dna-drft-key-qs-comment-response-20190826.pdf (Accessed February 17, 2021).

146 Charis Management Consulting I. *Review of Newborn Screening for Inborn Errors of Metabolism and Cystic Fibrosis: Synthesis Report*. 2006. URL: https://open.alberta.ca/dataset/24724e5c-2b9a-4a25-a2ac-bfd0678fc9fb/resource/6df326d0-b6cb-4d46-b936-4f999d020f74/download/3839488-2006-review-of-newborn-screening-for-inborn-errors-synthesis-report.pdf (Accessed February 17, 2021).

147 The Health Technology Assessment Unit University of Calgary. *Hepatitis C Screening in Alberta*. 2016. URL: https://open.alberta.ca/dataset/94508e51-c9ae-4777-971f-3484860f7ede/resource/cbb2a13f-2a0f-428d-b3e2-5af1c6d514d1/download/ahtdp-hepatitisc-screening-hta-report-2016.pdf (Accessed February 17, 2021).

148 Canadian Agency for Drugs and Technologies in Health. *Non-invasive Prenatal Testing: A Review of the Cost Effectiveness and Guidelines*. 2014. URL: https://www.cadth.ca/sites/default/files/pdf/htis/apr-2014/RC0520-NIPT-Final.pdf (Accessed February 17, 2021).

149 Canadian Agency for Drugs and Technologies in Health. *Screening for Hepatitis C: A Review*. 2017. URL: https://www.cadth.ca/sites/default/files/pdf/HT0014_HepC_InBrief_e.pdf (Accessed February 17, 2021).

150 Canadian Agency for Drugs and Technologies in Health. *Screening for Hepatitis C: A Review*. 2017. URL: https://www.cadth.ca/sites/default/files/pdf/HT0014_HepC_InBrief_e.pdf (Accessed February 17, 2021).

151 Canadian Agency for Drugs and Technologies in Health. *Thrombophilia Testing for Women Who Have Had Pregnancy Loss: Clinical Evidence, Cost-effectiveness, and Guidelines*. 2014. URL: https://www.cadth.ca/media/pdf/htis/dec-2014/RA0693 Thrombophilia in pregnancy Final.pdf (Accessed February 17, 2021).

152 Canadian Agency for Drugs and Technologies in Health. *Newborn Screening for Krabbe Leukodystrophy: A Review of the Clinical and Cost Effectiveness and Guidelines*. 2012. URL: https://www.cadth.ca/sites/default/files/pdf/htis/feb-2012/RC0328 Newborn screening for Krabbe Final.pdf (Accessed February 17, 2021).

153 Dziegiel M, Hedegaard M, Madsen C, Nilsson C, Pedersen H, Prahm K. *Føtal og neonatal alloimmun trombocytopeni (FNAIT): Gennemgang af den foreliggende litteratur med henblik på at forberede en national screenings indsats*. 2016. URL: https://www.dsog.dk/s/161218_FNAITP_guideline_foerste_udkast.pdf (Accessed February 17, 2021).

154 International Network of Agencies for Health Technology Assessment. *INAHTA Briefs Compilation 2009-2010*. 2010. URL: http://www.inahta.org/upload/Briefs_10/INAHTA Briefs Compilations volume 10.pdf (Accessed February 17, 2021).

155 International Network of Agencies for Health Technology Assessment. *INAHTA Briefs Compilation 2007-2008*. 2008. URL: https://www.inahta.org/upload/Briefs_8/INAHTA_Briefs_Compilation_8.pdf (Accessed February 17, 2021).

156 International Network of Agencies for Health Technology Assessment. *INAHTA Briefs Compilation 2006-2007*. 2007. URL: https://www.inahta.org/upload/Briefs_7/INAHTA_Briefs_Compilation_7.pdf (Accessed February 17, 2021).

157 Canadian Agency for Drugs and Technologies in Health. *Screening for Chlamydia Trachomatis and Neisseria Gonorrhoeae During Pregnancy: A Health Technology Assessment*. 2019. URL: https://www.inahta.org/upload/2019/19017_Screening for Chlamydia Trachomatis and Neisseria Gonorrhoeae During Pregnancy.pdf (Accessed February 17, 2021).

158 Ritchie, K; Quinn S. *Routine Ultrasound Scanning Before 24 Weeks of Pregnancy*. 2004. URL: https://www.inahta.org/upload/Briefs_4/0417_NHSQIS.pdf (Accessed February 17, 2021).

159 International Network of Agencies for Health Technology Assessment. *INAHTA Briefs Compilation 2001-2002*. 2002. URL: https://www.inahta.org/upload/Briefs_2/INAHTA_Briefs_Compilation_2.pdf (Accessed February 17, 2021).

160 Mohamad N. *Hepatitis B and Hepatitis C Screening Among High Risk Groups*. 2018. URL: https://www.inahta.org/upload/2018/18033_Hepatitis B and Hepatitis C Screening Among High Risk Groups.pdf (Accessed February 17, 2021).

161 International Network of Agencies for Health Technology Assessment. *INAHTA Briefs Compilation 2002-2003*. 2003. URL: https://www.inahta.org/upload/Briefs_3/INAHTA_Briefs_Compilation_3.pdf (Accessed February 17, 2021).

162 Greer I. *Screening for Thrombophilia in High-Risk Situations: Systematic Review and Cost-Effectiveness Analysis*. 2006. URL: https://www.inahta.org/upload/Briefs_7/06118_NCCHTA_Thrombophilia_HighRisk_Situations.pdf (Accessed February 17, 2021).

163 Estrada M, Guillén M, Iruretagoiena M, Taboada J, López de Argumedo M, Lapuente J, *et al. Description of the Current Status of Prenatal Screening in the Most Frequent Fetal Chromosopathies, Mainly Down Syndrome in Spain, and Proposals for the Improvement of Everyday Clinical Practice*. 2009. URL: http://www.inahta.org/upload/Briefs_9/09002_CAHTA_Description_Current_Status_Prenatal_Screening_Most_Frequent_Foetal_Chromosopathies.pdf (Accessed February 17, 2021).

164 International Network of Agencies for Health Technology Assessment. *INAHTA Briefs Compilation 2010-2011*. 2011. URL: http://www.inahta.org/upload/Briefs_11/1_Briefs Compilation 11_2.pdf (Accessed February 17, 2021).

165 Darus N. *Thyroid Screening in Pregnant Women*. 2009. URL: https://www.inahta.org/upload/Briefs_10/09086_MaHTAS_Thyroid_Screening_Pregnant_Women.pdf (Accessed February 17, 2021).

166 Institute of Health Economics. *The safety and efficacy/effectiveness of using automated testing devices for universal newborn hearing screening: an update*. 2012. URL: http://www.inahta.org/upload/Briefs_12/12026_The_safety_and_efficacy_effectiveness_of_using_automated_testing_devices_for_universal_newborn_hearing_screening.pdf (Accessed February 17, 2021).

167 Wald N. *First and Second Trimester Antenatal Screening for Down's Syndrome: The Results of the Serum, Urine and Ultrasound Screening Study (SURUSS)*. 2003. URL: https://www.inahta.org/upload/Briefs_4/0343_NCCHTA_Downs_Syndrome_SURUSS.pdf (Accessed February 17, 2021).

168 Institute of Health Economics. *First and second trimester prenatal screening update*. 2014. URL: http://www.inahta.org/upload/2014/14043_IHE_First and second trimester prenatal screening update.pdf (Accessed February 17, 2021).

169 Institute of Health Economics. *First and second trimester prenatal screening update*. 2014. URL: https://www.ihe.ca/download/first_and_second_trimester_prenatal_screening_update.pdf%0A (Accessed February 20, 2021).

170 Bricker L. *Ultrasound Screening in Pregnancy: A Systematic Review of the Clinical Effectiveness, Cost Effectiveness and Women's Views*. 2002. URL: http://www.inahta.org/upload/Briefs_3/02-66 NCCHTA - Ultrasound Screening in Pregnancy A Systematic Review of the Clinical Effectiveness, Cost Effectiveness and Women's Views.pdf (Accessed February 17, 2021).

171 Pandor A. *Clinical Effectiveness and Cost Effectiveness of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry: A Systematic Review*. 2004. URL: http://www.inahta.org/upload/Briefs_5/0479_NCCHTA_Neonatal_Screening_Inborn_Errors_Metabolism_Tandem_Mass_Spectrometry.pdf (Accessed February 17, 2021).

172 Institute of Health Economics. *Transcutaneous bilirubinometry for the screening of hyperbilirubinemia in neonates ≥35 weeks' gestation*. 2013. URL: http://www.inahta.org/upload/2013/13041_IHE_Transcutaneous bilirubinometry for the screening of hyperbilirubinemia in neonates.pdf (Accessed February 17, 2021).

173 Campbell S. *Screening for Postnatal Depression Within the Well Child Tamariki Ora Framework: An Economic Analysis of Implementation of a Screening Program*. 2008. URL: http://www.inahta.org/upload/Briefs_9/08094_HSAC_Screening_Postnatal_Depression_Within_Well_Child_Tamariki_Ora_Framework_Economic_Analysis_Implementation_Screening_Program.pdf (Accessed February 17, 2021).

174 de Wit G, Verweij A, van Baal P, Vijgen S, van den Berg M, Busch M, *et al. Economic evaluation of prevention: further evidence*. n.d. URL: https://www.rivm.nl/bibliotheek/rapporten/270091004.pdf (Accessed February 17, 2021).

175 Beraadsgroep Genetica van de Gezondheidsraad. *Neonatale screening op cystic fibrosis*. 2010. URL: http://www.rivm.nl/sites/default/files/2018-11/GRadviesCF_201001%2Cmaart 2010.pdf (Accessed February 17, 2021).

176 van Gils P, Tariq L, Hamberg-van Reenen H, van den Berg M. *Kosteneffectiviteit van preventie*. 2009. URL: https://www.rivm.nl/bibliotheek/rapporten/270091009.pdf (Accessed February 17, 2021).

177 Luc-Murk J, Wiersma T, Koelewijn J, van Leeuwen L, Jacobs P, Limburg Z, *et al. Rubellascreeningsbeleid bij zwangere vrouwen*. 2017. URL: https://lci.rivm.nl/sites/default/files/2017-06/Rubellascreeningsbeleid bij zwangere vrouwen LCI mei 2016.pdf (Accessed February 17, 2021).

178 Struijs J, de Wit G, Jager J. *Literatuuronderzoek naar kosten-effectiviteits-aspecten van de screening van zwangeren op syfillis ter preventie van congenitale syfillis*. n.d. URL: http://rivm.nl/bibliotheek/rapporten/403505007.pdf%0A (Accessed February 17, 2021).

179 van de Laar M, Beuker R, Rijlaarsdam J, van Duynhoven Y. *SOA en AIDS in Nederland*. 2000. URL: https://www.rivm.nl/bibliotheek/rapporten/441500011.pdf (Accessed February 17, 2021).

180 Statens beredning för medicinsk utvärdering. *Metoder för tidig fosterdiagnostik: En systematisk litteraturöversikt*. 2006. URL: https://www.sbu.se/contentassets/5c2bae2f615f4f3b91d9e08dfcbf7f64/fosterdiagnostik_fulltext .pdf (Accessed February 17, 2021).

181 Statens beredning för medicinsk utvärdering. *Blodprov för tidig upptäckt av Downs syndrom*. 2000. URL: https://www.sbu.se/contentassets/992e0260f40f459aa9dd4575eadfb4d2/blodprov_tidig_upptackt_downs_syndrom_2000.pdf (Accessed February 17, 2021).

182 National Institute for Health and Care Excellence. *High-throughput, non-invasive prenatal testing (NIPT) for fetal rhesus D status*. 2015. URL: https://www.nice.org.uk/guidance/dg25/documents/final-scope (Accessed February 17, 2021).

183 National Institute for Health and Care Excellence. *Twin and Triplet Pregnancy: [C] Evidence review for ultrasound screening for twin anaemia polycythaemia sequences*. 2019. URL: https://www.nice.org.uk/guidance/ng137/evidence/c-ultrasound-screening-for-twin-anaemia-polycythaemia-sequences-pdf-6898605375 (Accessed February 17, 2021).

184 National Institute for Health and Care Excellence. *Routine antenatal anti-D prophylaxis for RhD-negative women (review of technology appraisal guidance 41)*. 2008. URL: https://www.nice.org.uk/guidance/ta156/documents/pregnancy-rhesus-negative-women-routine-antid-review-overview2 (Accessed February 17, 2021).

185 National Institute for Health and Care Excellence. *Appendix A: summary of new evidence from 10-year surveillance of Postnatal care up to 8 weeks after birth (2006) NICE guideline CG37*. 2006. URL: https://www.nice.org.uk/guidance/cg37/evidence/appendix-a-summary-of-new-evidence-pdf-2736100910 (Accessed February 17, 2021).

186 Scott Shipman, S; Helfand, M; Nygren, P; Bougatsos C. *Screening for Developmental Dysplasia of the Hip*. 2006. URL: https://www.ahrq.gov/downloads/pub/prevent/pdfser/hipdyssyn.pdf (Accessed February 17, 2021).

187 Brunet, J; Blancquaert, I; St-Louis M. *Évaluation de la pertinence du dépistage néonatal sanguin par spectrométrie de masse en tandem de l'acidurie 3-hydroxy-3 méthylglutarique (HMG)*. 2020. URL: https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Depistage/INESSS_DepistageNeonatal_HMG.pdf (Accessed February 17, 2021).

188 Gemeinsame Bundesausschuss. *zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Kinder-Richtlinie: Screening von Neugeborenen zur Früherkennung von SCID*. 2018. URL: https://www.g-ba.de/downloads/40-268-5425/2018-11-22_Kinder-RL_SCID-Screening_TrG.pdf (Accessed February 17, 2021).

189 Unterausschuss Methodenbewertung. *Screening auf schwere congenitale Herzfehler mittels Pulsoxymetrie nach*. 2012. URL: https://www.g-ba.de/downloads/40-268-2400/2012-11-22_Einleitung-Beratungsverfahren-Pulsoxymetrie_Antrag-PatV.pdf (Accessed February 17, 2021).

190 Socialstyrelsen. *Screening för svår kombinerad immunbrist: Rekommendation och bedömningsunderlag*. 2019. URL: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-screeningprogram/2019-7-6225.pdf (Accessed February 17, 2021).

191 van den Berg, M; van Baal, PHM; de Wit, GA; Schuit A. *Kosteneffectiviteit van preventie: Literatuursignalering en modellering*. 2008. URL: https://www.rivm.nl/bibliotheek/rapporten/270091007.pdf (Accessed February 17, 2021).

192 Kauffman-de Boer, M; de Ridder Sluiter, H; Schuitema, T; Uilenburg, N; Vinks, E; van der Ploeg, K; Lanting, C; Oudshoorn, K; Verkerk P. *Implementatiestudie Neonatale Gehoorscreening*. 2001. URL: https://www.rivm.nl/sites/default/files/2018-11/Voorstudies implementatie neonatale gehoorscreening.pdf (Accessed February 17, 2021).

193 Ahya R, Turner ML, Urbaniak SJ, Snait Study T. Fetomaternal alloimmune thrombocytopenia. *Transfusion and Apheresis Science* 2001;**25**:139–45.

194 Alzarea A, Alolayan S, Almutairi H, Alqahtani S, Rittenhouse B. Re-Evaluating The Cost-Effectiveness of Screening For Congenital Adrenal Hyperplasia (CAH): The Sensitivity to Choice of Distributions In Probabilistic Sensitivity Analyses (PSAS). *Value in Health* 2015;**18**:A668.

195 Anderssen SH, Andresen J, Andersen R, Sponheim L. Universal neonatal hearing screening of infants with otoacoustic emissions. *Tidsskrift for Den Norske Laegeforening* 2002;**122**:2187–9.

196 Anonymous. Group B strep in pregnancy: Test-and-treat, or just treat? *Journal of Family Practice* 2008;**57**:11.

197 Bassett K, Lee PM, Green CJ, Mitchell L, Kazanjian A. Improving population health or the population itself? Health technology assessment and our genetic future. *International Journal of Technology Assessment in Health Care* 2004;**20**:106–14.

198 Bestwick J, Wald N. Cost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13. *PLoS ONE* 2019;**14**:e0220053.

199 Buser K, Bietenduwel A, Krauth C, Jalilvand N, Meyer S, Reuter G, *et al.* Model project of hearing screening in new-born in Hanover (preliminary results). *Gesundheitswesen* 2003;**65**:200–3.

200 Butt K, Crane J, Hutcheon J, Lim K, Nevo O. Universal Cervical Length Screening. *Journal of Obstetrics and Gynaecology Canada* 2019;**41**:363–74.

201 Cao-Nguyen MH, Kos MI, Guyot JP. Benefits and costs of universal hearing screening programme. *International Journal of Pediatric Otorhinolaryngology* 2007;**71**:1591–5.

202 Chaves F, Smith S, Xu DS. Universal screening for G6PD deficiency in pregnant women is not cost-effective. *American Journal of Clinical Pathology* 2004;**122**:634–5.

203 Clement MC, Mahlaoui N, Mignot C, le Bihan C, Rabetrano H, Hoang L, *et al.* Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia:

Analysis of cost-effectiveness based on French real field data. *Journal of Allergy and Clinical Immunology* 2015;**135**:1589–93.

204 Coop C, Edlin R, Brown J, Farquhar C. Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations. *BMJ Open* 2015;**5**:e006996.

205 Coskun B, Gulumser C, Coskun B, Artuk C, Karasahin KE. Impact of Syrian refugees on congenital TORCH infections screening in Turkey. *Journal of Obstetrics and Gynaecology Research* 2020;**46**:1017–24. https://doi.org/10.1111/jog.14273.

206 Crimmins S, Liu X, Doyle L, Harman C, Turan O. Universal QUAD screen versus universal cell free DNA testing for Down's syndrome screening: Cost-effectiveness analysis. *American Journal of Obstetrics and Gynecology* 2016;**214**:S381–2.

207 Cunningham L, Phipps H. A literature review and cost analysis comparing effectiveness of two Group B Streptococcus screening methods in term pregnancies. *Women and Birth* 2017;**30**:24. https://doi.org/10.1016/j.wombi.2017.08.062.

208 Ensari T, Kirbas A, Ozgu-Erdinc AS, Gokay Saygan S, Erkaya S, Uygur D, *et al.* An eight-year retrospective analysis of antenatal screening results for syphilis: is it still cost effective? *Journal of Infection in Developing Countries* 2015;**9**:1011–5.

209 Evans M, Krantz D, Hallahan T, Carmichael J. Combined first trimester screening for Down syndrome with nasal bone (NB) is cost advantageous over NIPS in younger advanced maternal age (AMA) patients. *American Journal of Obstetrics and Gynecology* 2014;**210**:S99.

210 Evans MI, Sonek JD, Hallahan TW, Krantz DA. Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies. *Ultrasound in Obstetrics and Gynecology* 2015;**45**:74–83.

211 Ferrier C, Khoshnood B, Dhombres F, Randrianaivo H, Perthus I, Jouannic JM, *et al.* Cost and outcomes of the ultrasound screening program for birth defects over time: a population-based study in France. *BMJ Open* 2020;**10**:e036566. https://doi.org/10.1136/bmjopen-2019-036566.

212 Galderisi A, Lolli E, Cavicchiolo ME, Bonadies L, Trevisanuto D, Baraldi E. The aftermath of SARS-CoV-2 in NICU: saving or checking accounts? Projected cost-effectiveness analysis. *European Journal of Pediatrics* 2021. https://doi.org/10.1007/s00431-020-03884-1.

213 Gogou M, Evangeliou A. Is Metabolic Screening Necessary in Children with Autism Spectrum Disorder? A Mini Review. *Journal of Pediatric Neurology* 2019;**17**:199–205.

214 Gorga MP, Neely ST. Cost-effectiveness and test-performance factors in relation to universal newborn hearing screening. *Mental Retardation and Developmental Disabilities Research Reviews* 2003;**9**:103–8.

215 Joubrel C, Gendron N, Dmytruk N, Touak G, Verlaguet M, Poyart C, *et al.* Comparative evaluation of 5 different selective media for Group B Streptococcus screening in pregnant women. *Diagnostic Microbiology and Infectious Disease* 2014;**80**:282–4.

216 Khurshid N, Connole S. To compare cost effectiveness for routine type and screen for patients undergoing cesarean section and vaginal delivery. *American Journal of Obstetrics and Gynecology* 2013;**208 (1 SUP**:S326–7.

217 Lee S, Lee E. Study on strategic approach of prenatal testing for trisomy 21 in general pregnancy population. *Clinical Chemistry* 2017;**63 (Supple**:S250.

218 Ong KJ, Soldan K, Jit M, Dunbar JK, Woodhall SC. Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all? *Sexually Transmitted Infections* 2017;**93**:18–24.

219 Qutub M, Klapper P, Vallely P, Cleator G. Genital herpes in pregnancy: is screening cost-effective? *International Journal of STD and AIDS* 2001;**12**:14–6. https://doi.org/10.1258/0956462011916677.

220 Rey E, Hudon L, Michon N, Boucher P, Ethier J, Saint-Louis P. Fasting plasma glucose versus glucose challenge test: screening for gestational diabetes and cost effectiveness. *Clinical Biochemistry* 2004;**37**:780–4.

221 Rosignoli L, Tonni G. Should cell-free fetal DNA be included in first trimester screening (FTS) for common trisomy? A possible scenario on 6697 women screened over 10 years. *Journal of Evaluation in Clinical Practice* 2016;**22**:899–906.

222 Rosselli D, Rueda JD, Ruiz-Patino A. Cost analysis of universal neonatal screening for inborn errors of metabolism with tandem mass spectrometry in Colombia. *Pediatria (Bucur)* 2014;**47**:68–73.

223 Stillwaggon E, Perez-Zetune V, Bialek SR, Montgomery SP. Congenital Chagas Disease in the United States: Cost Savings through Maternal Screening. *American Journal of Tropical Medicine and Hygiene* 2018;**98**:1733–42.

224 Teljeur C, O'Neill M, Harrington P. Some issues with the icer in technology assessments of screening interventions for rare conditions. *Value in Health* 2012;**15 (7)**:A280.

225 Thaler M, Biedermann R, Lair J, Krismer M, Landauer F. Cost-effectiveness of universal ultrasound screening compared with clinical examination alone in the diagnosis and treatment of neonatal hip dysplasia in Austria. *Journal of Bone and Joint Surgery* 2011;**93**:1126–30.

226 van Heyningen AM, Levenston MJ, Tamminga N, Scoop-Martijn EG, Wever RM, Verhagen AA, *et al.* Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-effectiveness of a universal screening programme for St. Maarten. *West Indian Medical Journal* 2009;**58**:301–4.

227 Wei D, Sardesai SR, Barton L. The c in torch: A cost-effective alternative to screening small-for-gestational-age infants. *Neonatology* 2014;**106**:24–9.

228 Seedat F, Taylor-Phillips S, Geppert J, Stinton C, Patterson J, Brown C, *et al. Universal antenatal culture-based screening for maternal Group B Streptococcus (GBS) carriage to prevent early-onset GBS disease*. 2016. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=654%0A (Accessed February 17, 2021).

229 UK National Screening Committee. *First trimester combined screening for trisomy 13 and trisomy 18*. 2013. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=451%0A (Accessed February 17, 2021).

230 UK National Screening Committee. *Newborn Screening for Duchenne Muscular Dystrophy*. 2016. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1029 (Accessed February 17, 2021).

231 UK National Screening Committee. *Newborn Screening for Duchenne Muscular Dystrophy*. 2011. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1028 (Accessed February 17, 2021).

232 Hawkes S, Gomez G. *Screening for syphilis in pregnancy*. 2013. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1183 (Accessed February 17, 2021).

233 UK National Screening Committee. *Screening for Preterm Labour in asymptomatic, low risk women*. 2014. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=992 (Accessed February 17, 2021).

234 UK National Screening Committee. *Screening for Preterm Labour in asymptomatic, low risk women*. 2014. URL: https://legacyscreening.phe.org.uk/policydb_download.php?doc=1117 (Accessed February 17, 2021).

235 Public Health England. *Newborn Pulse Oximetry Screening Pilot*. 2016. URL: https://legacyscreening.phe.org.uk/documents/pulse-oximetry/NPOSP End Project Report.pdf (Accessed February 17, 2021).

236 Medical Services Advisory Committee. *Application No. 1492 – Non-invasive prenatal testing (NIPT) for trisomies 21, 18 and 13*. 2019. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/B1BCB2807D09C12DCA258258000F2025/$File/1492 Final PSD.pdf (Accessed February 17, 2021).

237 Morona J, Newton S, Wang S, Tamblyn D, Ellery B, Merlin T. *Genetic testing for hereditary mutations in the VHL gene that cause von Hippel-Lindau syndrome*. 2012. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/3474C4A5A7E262E5CA25801000123B1A/$File/Final Report for VHL 31-7-2012 accessible2015.pdf (Accessed February 17, 2021).

238 Federaal Kenniscentrum voor de Gezondheidszorg. *Is Neonatale Screening op Mucoviscidose aangewezen in België?*. 2010. URL: https://kce.fgov.be/sites/default/files/atoms/files/kce_132a_neonatale_screening_op_mucoviscidose.pdf (Accessed February 17, 2021).

239 Canadian Task Force on Preventive Health Care. *Recommendations on Screening for asymptomatic bacteriuria in pregnancy*. 2018. URL: https://canadiantaskforce.ca/wp-content/uploads/2018/06/KTStakeholderDeck-Script-2018-05-11.pdf (Accessed February 17, 2021).

240 Canadian Task Force on Preventive Health Care. *Dépistage de la bactériurie asymptomatique pendant la grossesse*. n.d. URL: https://canadiantaskforce.ca/wp-content/uploads/2018/06/ASBPregnancy_KTdeck_Fr.pdf (Accessed February 17, 2021).

241 Wingert A, Pillay J, Featherstone R, Gates M, Sebastianski M, Shave K, *et al. Screening for Asymptomatic Bacteriuria in Pregnancy: Systematic Review & Meta-analysis*. 2017. URL: https://canadiantaskforce.ca/wp-content/uploads/2019/03/Screening-for-Asymptomatic-Bacteriuria-in-Pregnancy-Final-Report-Appendices-13Oct2017.pdf (Accessed February 17, 2021).

242 Makni H, St-Hilaire C, Robb L, Larouche K, Blancquaert I. *Tandem Mass Spectrometry and Neonatal Blood Screening in Quebec*. 2007. URL: https://www.inesss.qc.ca/fileadmin/doc/AETMIS/Rapports/DepistageGenetique/2007_03_en.pdf (Accessed February 17, 2021).

243 Fröschl B, Brunner-Ziegler S, Wirl C. *Prävention des fetalen Alkoholsyndroms*. 2013. URL: https://portal.dimdi.de/de/hta/hta_berichte/hta330_bericht_de.pdf (Accessed February 17, 2021).

244 Gemeinsamer Bundesausschuss. *zum Beschluss des Gemeinsamen Bundesaus-schusses über eine Änderung der Gesundheitsuntersuchungs-Richtlinie (GU-RL): Einführung eines Screenings auf Hepatitis-B- und auf Hepatitis-C-Virusinfektion*. 2020. URL: https://www.g-ba.de/downloads/40-268-7078/2020-11-20_GU-RL_Screening-Hepatitis-B-und-C_TrG.pdf (Accessed February 17, 2021).

245 Statens beredning för medicinsk utvärdering. *Analys av foster-DNA i kvinnans blod: icke-invasiv fosterdiagnostik (NIPT) för trisomi 13, 18 och 21*. 2015. URL: https://www.sbu.se/contentassets/0dcc05c3977b45bcb598a20909f2d07b/analys_foster-dna_kvinnans_blod_icke-invasiv_fosterdiagnostik_nipt_201503.pdf (Accessed February 17, 2021).

246 National Institute for Health and Care Excellence. *Twin and Triplet Pregnancy: [A] Evidence review for ultrasound screening for feto-fetal transfusion syndrome*. 2019. URL: https://www.nice.org.uk/guidance/ng137/evidence/a-ultrasound-screening-for-fetofetal-transfusion-syndrome-pdf-6898605373 (Accessed February 17, 2021).

247 Unterausschuss Methodenbewertung. *SGB V auf Bewertung eines Neugeborenenscreenings auf Spinale*. 2019. URL: https://www.g-ba.de/downloads/40-268-5424/2019-11-22_Einleitung-Beratungsverfahren-Screening-spinale-Muskelatrophie_Antrag-PatV.pdf (Accessed February 17, 2021).

248 Albright C, Werner E, Anderson B. Universal cytomegalovirus screening in pregnancy: A cost-effectiveness analysis. *American Journal of Obstetrics and Gynecology* 2015;**212**:S307–8.

249 Berruti A, Gift T. Cost and cost-effectiveness of antenatal screening for congenital syphilis in the U.S. *Sexually Transmitted Diseases* 2018;**45 (Supple**:S70.

250 Bert F, Gualano MR, Biancone P, Brescia V, Camussi E, Martorana M, *et al.* HIV-screening in pregnant women: a systematic review of cost-effectiveness studies. *European Journal of Public Health* 2016;**26**:341.

251 Bessey A, Chilcott J, Pandor A, Paisley S. The Cost-Effectiveness of Expanding the Nhs Newborn Bloodspot Screening Programme To Include Homocystinuria (Hcu), Maple Syrup Urine Disease (Msud), Glutaric Aciduria Type 1 (Ga1), Isovaleric Acidaemia (Iva), and Long-Chain Hydroxyacyl-Coa Dehydrogenase D. *Value in Health* 2014;**17**:A531.

252 Bessey A, Leaviss J, Galvan De la Cruz C, Chilcott J, Wong R. The cost-effectiveness of screening for severe combined immunodeficiency (SCID) in the UK NHS newborn bloodspot screening programme. *Value in Health* 2017;**20 (9)**:A501.

253 Bessos H, Turner M, Fagge T, Harkness M, Rentoul F, Seymour J, *et al.* Health economic evaluation of the cost effectiveness of antenatal screening for HPA-1a induced neonatal alloimmune thrombocytopenia (NAIT). *Transfusion (Paris)* 2003;**43**:38A-38A.

254 Beulen L, Grutters JPC, Bekker MN, van Vugt JMG. The implementation of noninvasive prenatal diagnosis in national health care: A decision-analytic economic model. *Prenatal Diagnosis* 2013;**33**:69.

255 Caughey A, Norton M, Kuppermann M, Washington AE. First vs. second trimester screening tools for Down syndrome: A cost-utility analysis. *American Journal of Obstetrics and Gynecology* 2001;**185**:S224–S224. https://doi.org/10.1016/s0002-9378(01)80558-5.

256 Chaillon A, Reau N, Rand E, Martin N. The Cost-Effectiveness of HCV Screening of Pregnant Women in the United States. *Hepatology* 2018;**68**:573A-574A.

257 Chilcott J, Bessey A, Leaviss J, Sutton A. Potential cost-effectiveness of including screening for x-linked adrenoleukodystrophy in the UK national health service newborn blood spot screening program. *Journal of Inborn Errors of Metabolism and Screening* 2017;**5**:43–4.

258 Chowers M, Shavit O. Economic evaluation of universal antenatal HIV screening compared with current “at risk” policy in Israel. *Value in Health* 2013;**16 (7)**:A359.

259 Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for inherited metabolic disorders using tandem mass spectrometry. *Value in Health* 2005;**8**:298. https://doi.org/10.1016/s1098-3015(10)62762-3.

260 Donnay S, Balsa JA, Alvarez J, Crespo C, Perez-Alcantara F, Villacampa A, *et al.* Cost-effectiveness of universal screening for thyroid disease in pregnant women in Spain. *Value in Health* 2013;**16**:A438–A438. https://doi.org/10.1016/j.jval.2013.08.662.

261 Dosiou C, Barnes J, Schwartz A, Negro R, Crapo LM, Stagnaro-Green A. Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. *Thyroid* 2011;**21**:A9–10.

262 Hamel M, Orzechowski K, Berghella V, Thung S, Werner E. Cost-effectiveness of transvaginal ultrasound cervical length screening in singletons without prior preterm birth: An update. *American Journal of Obstetrics and Gynecology* 2015;**212**:S90–1.

263 Hersh AR, Megli CJ, Caughey AB. Universal repeat screening for syphilis in the third trimester of pregnancy: a cost-effective analysis. *American Journal of Obstetrics and Gynecology* 2017;**216**:S183–S183. https://doi.org/10.1016/j.ajog.2016.11.556.

264 Hillman SC, Barton PM, Roberts TE, Maher ER, Kilby MD. Chromosomal microarray (CMA) use for the prenatal detection of chromosome anomalies: Model-based health economic evaluation. *Archives of Disease in Childhood: Fetal and Neonatal Edition* 2013;**98**:.

265 Hopkins M, Dugoff L, Durnwald C, Havrilesky L, Dotters-Katz S. Cell-free DNA for Down syndrome screening in morbidly obese women: Is it a cost-effective strategy? *American Journal of Obstetrics and Gynecology* 2019;**220 (1 Sup**:S583–4.

266 Ibekwe E, Francis Fatoye F, Haigh C. Economic impact of routine opt-out antenatal HIV screening: A systematic review. *Value in Health* 2017;**20 (5)**:A353.

267 Keren R, Helfand M, Homer CJ, McPhillips H, Lieu T. Projected cost-effectiveness of statewide universal newborn hearing screening. *Pediatric Research* 2002;**51**:160A-160A.

268 Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Cost-utility analysis of antenatal screening for neonatal alloimmune thrombocytopenia. *Vox Sanguinis* 2006;**91**:263.

269 Little S, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey A. The cost-effectiveness of prenatal screening for spinal muscular atrophy. *American Journal of Obstetrics and Gynecology* 2009;**201**:S37.

270 Londono D, Taborda A, Dominguez MT, Sandoval NS, Troncoso GT, Fonseca AF, *et al.* Cost-effectiveness analysis of neonatal screening with pulse oximetry for the detection of critical congenital heart disease in Colombia, 2017. *Value in Health* 2017;**20 (9)**:A587.

271 Mahlaoui N, Clement M, Mignot C, le Bihan C, Rabetrano H, Hoang LY, *et al.* Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on french real field data. *Journal of Clinical Immunology* 2014;**34**:S162.

272 Masucci L, Bryan S, Kaczorowski J, Collet JP, Schreiber RA. Cost-effectiveness analysis of universal newborn screening strategies for biliary atresia. *Gastroenterology* 2017;**152 (5 Sup**:S1157.

273 Masucci L, Bryan S, Kaczorowski JA, Collet JP, Schreiber RA. The cost-effectiveness of universal screening for biliary atresia in Canada. *Hepatology* 2011;**54**:595A-596A.

274 Masucci L, Schreiber RA, Kaczorowski J, Collet JP, Bryan S. Universal screening of newborns for biliary atresia: A cost-effectiveness comparison of alternative strategies. *Canadian Liver Journal* 2018;**1 (1)**:100.

275 McGhee SA, McCabe ERB, Stiehm ER. Cost-effectiveness of newborn screening for severe combined immunodeficiency. *Journal of Investigative Medicine* 2004;**52**:S127–S127. https://doi.org/10.1097/00042871-200401001-00274.

276 Mission J, Ohno M, Yanit K, Cheng Y, Caughey A. Gestational diabetes screening with the new IADPSG 2 hour glucose tolerance test vs the 1 hour glucose challenge test: A cost-effectiveness analysis. *American Journal of Obstetrics and Gynecology* 2012;**206**:S126.

277 Mogul D, Zhou M, Intihar P, Schwarz KB, Frick K. Cost-effective analysis of screening for biliary atresia with the stool color card. *Hepatology* 2013;**58**:216A.

278 Mone F, Mulcahy C, McParland P, O'Mahony J, Tyrell E, Breathnach F, *et al.* A randomised controlled trial and cost-effectiveness analysis of low dose aspirin with an early screening test for preeclampsia in low risk women. *Reproductive Sciences* 2017;**24 (1 Supp**:68A.

279 Mukerji A, Shafey A, Jain A, Cohen E, Shah P, Shah V, *et al.* Cost-effectiveness of pulse oximetry screening for critical congenital heart defects in Ontario. *Paediatrics & Child Health* 2018;**23 (Supple**:e17–8.

280 Nshimyumukiza L, Bois A, Daigneault P, Lands L, Laberge A, Fournier D, *et al.* Simulation of cost-effectiveness of newborn screening for cystic fibrosis in the province of Quebec (Canada). *Pediatric Pulmonology* 2013;**48**:381.

281 O'Mahony JF, Mone F, Tyrrell E, Mulcahy C, McParland P, Breathnach F, *et al.* The cost effectiveness of a policy of universal aspirin versus aspirin indicated by a positive pre-eclampsia screening test. *American Journal of Obstetrics and Gynecology* 2017;**216 (1 Sup**:S483.

282 Peterson C, Grosse SD, Cassell CH, Oster ME, Olney RS. A cost-effectiveness analysis of universal pulse oximetry screening to detect critical congenital heart disease in U.S. Newborns. *Circulation* 2012;**5**:.

283 Pfeil J, Listl S, Hoffmann GF, Kolker S, Lindner M, Burgard P. Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: A cost-effectiveness analysis. *Molecular Genetics and Metabolism* 2014;**111 (3)**:299.

284 Pinto N, Nelson R, Smith K, Metz TD, Puchalski M. Cost-effectiveness of prenatal screening strategies for congenital heart disease (CHD). *Journal of the American Society of Echocardiography* 2012;**25 (6)**:B27.

285 Rours GIJG, Verkooijen RP, Verbrugh HA, Postma MJ. Cost-effectiveness of screening for chlamydia trachomatis in dutch pregnant women. *Sexually Transmitted Infections* 2011;**87**:A61–2.

286 Schwartz PJ, Quaglini S, Rognoni C, Spazzolini C, Mannarino S, Priori SG. Cost-effectiveness of neonatal ECG screening the long QT syndrome. *European Heart Journal* 2005;**26**:552.

287 Sicuri E, Munoz J, Pinazo MJ, Posada E, Sanchez J, Alonso P, *et al.* Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non-endemic area. *Tropical Medicine and International Health* 2009;**14**:241.

288 Sinkey R, Odibo A. Screening strategies for vasa previa during the mid-trimester ultrasound: A decision and cost-effective analysis. *American Journal of Obstetrics and Gynecology* 2016;**214**:S257.

289 Thung SF, Grobman WA. The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus 1 and 2 antibodies. *American Journal of Obstetrics and Gynecology* 2003;**189**:S97–S97. https://doi.org/10.1016/j.ajog.2003.10.115.

290 Urbanus A, van Keep M, Matser A, Rozenbaum M, Weegink C, van den Hoek A, *et al.* Is adding HCV screening to the antenatal national screening program in Amsterdam, The Netherlands cost-effective? *Journal of Hepatology* 2013;**58**:S22–S22. https://doi.org/10.1016/s0168-8278(13)60052-5.

291 van der Ploeg CP, Vernooij-van Langen AM, van den Akker-Van Marle ME, Elvers B, Gille H, Dankert-Roelse JE. Cost-effectiveness of neonatal screening for cystic fibrosis. *Pediatric Pulmonology* 2010;**45**:394.

292 Venditti CP, Venditti LN, Kaplan PB, Kaye EM, Glick H, Stanley CA, *et al.* Newborn screening by tandem mass spectrometry for medium chain Acyl-CoA dehydrogenase deficiency: Is it cost effective? *Pediatric Research* 2002;**51**:225A-226A.

293 Waites BT, Walker AR, Skeith AE, Caughey AB. First trimester fasting plasma glucose screen in advanced maternal age to detect pre-existing glucose intolerance. *Obstetrics and Gynecology* 2018;**131 (Suppl**:168S.

294 Walker AR, Valent A, Caughey AB. Positivity thresholds of HbA1c assay as a screening test for gestational diabetes mellitus in the first trimester in high-risk populations. *American Journal of Obstetrics and Gynecology* 2017;**216 (1 Sup**:S291–2.

295 Wastlund D, Moraitis A, Dacey A, Sovio U, Wilson E, Smith G. Screening for breech presentation using late pregnancy ultrasonography: a prospective cohort study and cost-effectiveness analysis. *BJOG: An International Journal of Obstetrics & Gynaecology* 2019;**126**:125.

296 Wastlund D, Moraitis A, Thornton J, Sanders J, White I, Brocklehurst P, *et al.* The cost-effectiveness of universal late pregnancy ultrasound screening for fetal macrosomia in low-risk women. *BJOG: An International Journal of Obstetrics & Gynaecology* 2019;**126**:123.

297 Werner E, Han C, Pettker C, Buhimschi C, Copel J, Funai E, *et al.* Universal cervical length screening to prevent preterm birth: A cost-effectiveness analysis. *American Journal of Obstetrics and Gynecology* 2009;**201**:S224–5.

298 Werner EF, Pettker CM, Reel M, Zuckerwise LC, Funai EF, Thung SF. Long term diabetes risk reduction necessary for gestational diabetes screening to be cost effective. *American Journal of Obstetrics and Gynecology* 2012;**206**:S122–3.

299 Zantow E, Williams M, Turrentine M. Evaluating the cost effectiveness of the latest recommendations for Group B Streptococcus screening. *American Journal of Obstetrics and Gynecology* 2020;**222 (1 Sup**:S488.

300 Zhang W, Mohammadi T, Sou J, Anis A. Pns52 Can Cost-Effectiveness Analysis Inform the Extent of Coverage under Public Healthcare? A Microsimulation Model of Alternative Prenatal Screening and Diagnostic Strategies. *Value in Health* 2019;**22 (Supple**:S295.

301 Adams EJ, Turner KM, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. *Sexually Transmitted Infections* 2007;**83**:267–74.

302 Allan WC, Timothy K, Vincent GM, Palomaki GE, Neveux LM, Haddow JE. Long QT syndrome in children: the value of rate corrected QT interval and DNA analysis as screening tests in the general population. *Journal of Medical Screening* 2001;**8**:173–7.

303 Allen A, Shaffer BL, Caughey AB, Pilliod RA. Nuchal translucency ultrasound in women with low risk cell free DNA screening: A cost-effectiveness analysis. *American Journal of Obstetrics and Gynecology* 2020;**222 (1 Sup**:S517.

304 Askew A, Heine RP, Myers E, Swamy G. Cost-effectivenss of penicillin skin testing in GBS plus pregnant women with penicillin allergy. *American Journal of Obstetrics and Gynecology* 2015;**212**:S300–S300. https://doi.org/10.1016/j.ajog.2014.10.809.

305 Barbosa C, Smith E, Hoerger T, Fenlon N, Schillie S, Bradley C, *et al.* Cost-effectiveness analysis of the national Perinatal Hepatitis B Prevention Program. *Pediatrics* 2014;**133**:243–53.

306 Beauchamp KA, Johansen Taber KA, Muzzey D. Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. *Genetics in Medicine* 2019;**21**:1948–57.

307 Bernstein KT, Mehta SD, Rompalo AM, Erbelding EJ. Cost-effectiveness of screening strategies for gonorrhea among females in private sector care. *Obstetrics and Gynecology* 2006;**107**:813-821\.

308 Desplanches T, Lejeune C, Cottenet J, Sagot P, Quantin C. Cost-effectiveness of diagnostic tests for threatened preterm labor in singleton pregnancy in France. *Cost Effectiveness and Resource Allocation* 2018;**16**:21.

309 Gray A, Elbourne D, Dezateux C, King A, Quinn A, Gardner F. Economic evaluation of ultrasonography in the diagnosis and management of developmental hip dysplasia in the United Kingdom and Ireland. *Journal of Bone and Joint Surgery* 2005;**87**:2472–9.

310 Greeley SA, John PM, Winn AN, Ornelas J, Lipton RB, Philipson LH, *et al.* The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. *Diabetes Care* 2011;**34**:622-627\.

311 Grimshaw GM, Szczepura A, Hulten M, MacDonald F, Nevin NC, Sutton F, *et al.* Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities. *Health Technology Assessment* 2003;**7**:1–146.

312 Harris RA, Washington AE, Nease Jr. RF, Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. *The Lancet* 2004;**363**:276–82.

313 Jacklin PB, Maresh MJ, Patterson CC, Stanley KP, Dornhorst A, Burman-Roy S, *et al.* A cost-effectiveness comparison of the NICE 2015 and WHO 2013 diagnostic criteria for women with gestational diabetes with and without risk factors. *BMJ Open* 2017;**7**:e016621.

314 Jackson KM, Scott KE, Graff Zivin J, Bateman DA, Flynn JT, Keenan JD, *et al.* Cost-utility analysis of telemedicine and ophthalmoscopy for retinopathy of prematurity management. *Archives of Ophthalmology* 2008;**126**:493-499\.

315 MacDonell-Yilmaz R, Anderson K, DeNardo B, Sprinz P, Padula W v. Cost-effectiveness Analysis of Screening Extremely Low Birth Weight Children for Hepatoblastoma Using Serum Alpha-fetoprotein. *Journal of Pediatrics* 2020;**225**:80-89 e4. https://doi.org/10.1016/j.jpeds.2020.05.041.

316 Porter HL, Neely ST, Gorga MP. Using benefit-cost ratio to select Universal Newborn Hearing Screening test criteria. *Ear and Hearing* 2009;**30**:447–57.

317 Toledano-Alhadef H, Basel-Vanagaite L, Magal N, Davidov B, Ehrlich S, Drasinover V, *et al.* Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. *American Journal of Human Genetics* 2001;**69**:351–60.

318 Ulph F, Wright S, Dharni N, Payne K, Bennett R, Roberts S, *et al.* Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project. *Health Technology Assessment* 2017;**21**:1–240.

319 Liufu V, Mundy L, Hiller J. *Screening for gestational diabetes*. 2008. URL: https://www1.health.gov.au/internet/horizon/publishing.nsf/Content/BB580B674729F620CA2575AD0080F351/$File/Volume_21_Update_Aug_2008_Gestational_Diabetes.pdf (Accessed February 17, 2021).

320 Medical Services Advisory Committee. *Application No. 1531 – Alpha Thalassaemia genetic testing*. 2019. URL: https://www1.health.gov.au/internet/msac/publishing.nsf/Content/BDB27F8F2CD7839DCA2583B7000013BA/$File/1531 Final PSD-Mar2019.pdf (Accessed February 17, 2021).

321 Myrhaug H, Reinar L, Stoinska-Schneider A, Hval G, Movik E, Brurberg K, *et al. Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia*. 2020. URL: https://www.fhi.no/contentassets/902cc5b12aa94c01a8199a28239b052d/safety-clinical-effectiveness-predictive-accuracy-and-cost-effectiveness-of-blood-based-tests-for-women-with-suspected-preeclampsia-hta-2020.pdf (Accessed February 17, 2021).

322 National Institute for Public Health and the Environment. *Chlamydia Screening Implementation Netherlands: Impact evaluation and cost-effectiveness*. 2010. URL: https://www.rivm.nl/bibliotheek/rapporten/210261008.pdf (Accessed February 17, 2021).

323 Lewis, D; Barham L. *Economic Modelling of Interventions to Reduce the Transmission of Chlamydia and other Sexually Transmitted Infections and to Reduce the Rate of Under Eighteen Conceptions*. 2006. URL: https://www.nice.org.uk/guidance/ph3/evidence/economic-modelling-report-pdf-124482061 (Accessed February 17, 2021).

324 Adeniji AA, Fuller I, Dale T, Lindow SW. Should we continue screening rhesus D positive women for the development of atypical antibodies in late pregnancy? *Journal of Maternal-Fetal and Neonatal Medicine* 2007;**20**:59–61.

325 Barre S, Corbillon E. Economic evaluation of strategies for screening newborns for bilateral hearing impairment in France. *Value in Health* 2006;**9**:A139–40. https://doi.org/10.1016/s1098-3015(10)64737-7.

326 Dangouloff T, Hiligsmann M, Caberg J, Boemer F, Servais L. Development of a decision-analytic model for the economic evaluation of newborn screening for spinal muscular atrophy. *Neuromuscular Disorders* 2018;**28**:S59–S59. https://doi.org/10.1016/j.nmd.2018.06.125.

327 Dangouloff T, Servais L, Hiligsmann M. SMA: Registries, Biomarkers & Outcome Measures. *Neuromuscular Disorders* 2020;**30**:. https://doi.org/10.1016/j.nmd.2020.08.193.

328 Finegold DN, Naylor EW, Chace DH, Kamlet M. Cost effectiveness of tandem mass spectrometry (MS/MS) for neonatal screening: Medium chain acyl-CoA dehydrogenase (MCAD) as a model. *American Journal of Human Genetics* 2001;**69**:443.

329 Kingston D, Kingston D, McDonald S, Biringer A, Austin MP, McDonald SD, *et al.* Comparing the Acceptability, Clinical-, and Cost-effectiveness of Mental Health E-screening to Paper-based Screening in Pregnant Women: a Randomized, Parallel-group, Superiority Trial. *European Psychiatry* 2015;**30**:. https://doi.org/10.1016/s0924-9338(15)30773-2.

330 Komakech H, Muhumuza C, Lamorde M, Marques E, Kuznik A. The cost-effectiveness of antenatal syphilis screening using point-of-care testing in Latin America. *Value in Health* 2014;**17 (3)**:A160.

331 Korres S, Nikolopoulos TP, Komkotou V, Balatsouras D, Kandiloros D, Constantinou D, *et al.* Newborn hearing screening: effectiveness, importance of high-risk factors, and characteristics of infants in the neonatal intensive care unit and well-baby nursery. *Otology and Neurotology* 2005;**26**:1186–90.

332 Munster JM, Leenders A, van der Hoek W, Schneeberger PM, Rietveld A, Riphagen-Dalhuisen J, *et al.* (Cost-) Effectiveness of a Screening Strategy for Q Fever among Pregnant Women in Risk Areas: A Clustered Randomized Controlled Trial. *Pharmacoepidemiology and Drug Safety* 2011;**20**:S50–1.

333 Thomas C, Mirallie S, Durand-Zaleski I, Sebille V, Mahlaoui N, Fischer A, *et al.* Clinical and cost-effectiveness prospective study of neonatal screening for severe combined immunodeficiency using the t-cell receptor excision circles assay in a french multicentre study. *Journal of Clinical Immunology* 2014;**34**:S377.

334 Anonymous. Noninvasive prenatal testing for trisomies 21, 18, and 13, sex chromosome aneuploidies, and microdeletions: A health technology assessment. *Ontario Health Technology Assessment Series* 2019;**19**:1–166.

335 Kanga I, Williams D, Hatchette T, MacKinnon S, Jung H, Black C, *et al.* Screening for Chlamydia Trachomatis and Neisseria Gonorrhoeae During Pregnancy: A Health Technology Assessment. *Canadian Agency for Drugs and Technologies in Health* 2018.

336 Konomura K, Tamura Y, Akazawa M, Fukuda T. Cost-utility analysis of newborn screening program by tandem mass spectrometry in Japan. *Value in Health* 2019;**22**:S632–S632.

337 Krantz DA, Hallahan TW, Carmichael JB, Liu H-P. First trimester screening for early onset preeclampsia is a cost effective approach in prenatal care. *Pregnancy Hypertension* 2015;**5**:92. https://doi.org/10.1016/j.preghy.2014.10.185.

338 Ramos Gon J, Serrano Aguilar P, Saenz-Torres M, Posada M. Cost-effectiveness of neonatal screening for congenital errors of metabolism using tandem mass spectrometry. *Value in Health* 2009;**12 (3)**:A164.

339 Torres YAM, Rojas JAD, Garay OAG. Cost effectiveness of universal neonatal hearing screening with otoacoustic emissions and/or automated auditory brainstem response, for the detection of bilateral congenital hearing loss and early treatment, in newborns without risk factors, in Colombia. *Value in Health* 2017;**20**:A586–7.

340 Wetzel S, Miller ES, Cirino N, Dukhovny D, Ameel B, Caughey AB. Routine antenatal screening for depression: What are the outcomes and is it cost-effective? *American Journal of Obstetrics and Gynecology* 2016;**214**:S383–4.

341 Vass CM, Georgsson S, Ulph F, Payne K. Preferences for aspects of antenatal and newborn screening: A systematic review. *BMC Pregnancy and Childbirth* 2019;**19**:1–11. https://doi.org/10.1186/S12884-019-2278-7/TABLES/2.

342 Carroll F, Al-Janabi H, Flynn T, Montgomery A. Women and their partners' preferences for Down's syndrome screening tests: a discrete choice experiment. *Prenatal Diagnosis* 2013;**33**:449–56.

343 Beulen L, Grutters JPC, Faas BHW, Feenstra I, Groenewoud H, van Vugt JMG, *et al.* Women's and healthcare professionals' preferences for prenatal testing: A discrete choice experiment. *Prenatal Diagnosis* 2015;**35**:549–57. https://doi.org/10.1002/pd.4571.